(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
IDF destroys Hezbollah rocket launcher used in large rocket salvo towards Haifa, Galilee - 2Inn The executives: A Remunerating Profession Decision for Energetic People
- 3How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- 4Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- 5Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
- Why haven’t humans been back to the moon in over 50 years?
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis
- The most effective method to Make a Dazzling Site in 5 Basic Advances
- What to watch for as NASA’s historic Artemis II crew prepares to lift off toward the moon
- When faith comes under fire: How Iran’s repression of religious minorities has increased
- German police 'cleared path for fascists with batons,' protesters say
- NASA's Artemis astronauts enter final preparations for Moon mission
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
